nature portfolio

Corresponding author(s): Xuefeng Guo

Last updated by author(s): 2023-02-06

# Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist.

Please do not complete any field with "not applicable" or n/a. Refer to the help text for what text to use if an item is not relevant to your study.
For final submission: please carefully check your responses for accuracy; you will not be able to make changes later.

## Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- [x] The exact sample size (*n*) for each experimental group/condition, given as a discrete number and unit of measurement
- [x] A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- [x] The statistical test(s) used AND whether they are one- or two-sided
  *Only common tests should be described solely by name; describe more complex techniques in the Methods section.*
- [x] A description of all covariates tested
- [x] A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- [ ]

- [x] A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- [ ] For null hypothesis testing, the test statistic (e.g. *F*, *t*, *r*) with confidence intervals, effect sizes, degrees of freedom and *P* value noted
  *Give P values as exact values whenever suitable.*
- [ ] For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- [x] For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- [ ] Estimates of effect sizes (e.g. Cohen's *d*, Pearson's *r*), indicating how they were calculated

*Our web collection on statistics for biologists contains articles on many of the points above.*

## Software and code

Policy information about availability of computer code

| | |
|---|---|
| Data collection | The I–t curves and IETS were sampled by the HF2LI lock-in amplifier at constant bias. The current signal was amplified by a DL1211 amplifier and |
| Data analysis | The I–t curves can be analysed by the QuB software. |

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

## Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The data that supports the findings of this study is available from the corresponding authors upon request.

## Human research participants

Policy information about studies involving human research participants and Sex and Gender in Research.

| | |
|---|---|
| Reporting on sex and gender | This study does not involve human research participants. |
| Population characteristics | See above. |
| Recruitment | Not applicable. |
| Ethics oversight | Not applicable. |

Note that full information on the approval of the study protocol must also be provided in the manuscript.

# Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

○ Life sciences ○ Behavioural & social sciences ◉ Ecological, evolutionary & environmental sciences

# Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

| | |
|---|---|
| Sample size | |
| Data exclusions | |
| Replication | |
| Randomization | |
| Blinding | |

# Behavioural & social sciences study design

All studies must disclose on these points even when the disclosure is negative.

| | |
|---|---|
| Study description | |
| Research sample | |
| Sampling strategy | |
| Data collection | |
| Timing | |
| Data exclusions | |
| Non-participation | |
| Randomization | |

# Ecological, evolutionary & environmental sciences study design

All studies must disclose on these points even when the disclosure is negative.

| | |
|---|---|
| Study description | We described a carbon-based single-molecule device to meet the demand of the miniaturization of electronic devices and decipher the |
| Research sample | A single molecule was covalently integrated into the graphene electrodes through chemical engineering. |
| Sampling strategy | An in-situ real-time electrical single-molecule detection which has the capability of single-event tracking |
| Data collection | The current signal of the molecular loop was amplified by a DL1211 amplifier. |
| Timing and spatial scale | The current signal recorded by a high-speed acquisition card from NIDAQ at a rate of 28,800 samples per second. |
| Data exclusions | No data are excluded from the analyses. |
| Reproducibility | The single-molecule connection were highly reproducible. |
| Randomization | The I–t curves can be analysed by the QuB software. |

Blinding: We idealized the current fluctuations using the QuB software and measured the dwell times in each current level.

Did the study involve field work? ○ Yes ◉ No

## Field work, collection and transport

Field conditions

Location

Access & import/export

Disturbance

# Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

### Materials & experimental systems

| n/a | Involved in the study |
|---|---|
| ○ | Antibodies |
| ○ | Eukaryotic cell lines |
| ○ | Palaeontology and archaeology |
| ○ | Animals and other organisms |
| ○ | Clinical data |
| ○ | Dual use research of concern |

### Methods

| n/a | Involved in the study |
|---|---|
| ○ | ChIP-seq |
| ○ | Flow cytometry |
| ○ | MRI-based neuroimaging |

## Antibodies

Antibodies used

Validation

## Eukaryotic cell lines

Policy information about cell lines and Sex and Gender in Research

Cell line source(s)

Authentication

Mycoplasma contamination

Commonly misidentified lines
(See ICLAC register)

## Palaeontology and Archaeology

Specimen provenance

Specimen deposition

Dating methods

☐ Tick this box to confirm that the raw and calibrated dates are available in the paper or in Supplementary Information.

Ethics oversight

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Animals and other research organisms

Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research, and Sex and Gender in Research

Laboratory animals

Wild animals

Reporting on sex

Field-collected samples

Ethics oversight

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Clinical data

Policy information about clinical studies

All manuscripts should comply with the ICMJE guidelines for publication of clinical research and a completed CONSORT checklist must be included with all submissions.

Clinical trial registration

Study protocol

Data collection

Outcomes

## Dual use research of concern

Policy information about dual use research of concern

### Hazards

Could the accidental, deliberate or reckless misuse of agents or technologies generated in the work, or the application of information presented in the manuscript, pose a threat to:

| No | Yes | |
|---|---|---|
| ○ | ○ | Public health |
| ○ | ○ | National security |
| ○ | ○ | Crops and/or livestock |
| ○ | ○ | Ecosystems |
| ○ | ○ | Any other significant area |

### Experiments of concern

Does the work involve any of these experiments of concern:

| No | Yes | |
|---|---|---|
| ○ | ○ | Demonstrate how to render a vaccine ineffective |
| ○ | ○ | Confer resistance to therapeutically useful antibiotics or antiviral agents |
| ○ | ○ | Enhance the virulence of a pathogen or render a nonpathogen virulent |
| ○ | ○ | Increase transmissibility of a pathogen |
| ○ | ○ | Alter the host range of a pathogen |
| ○ | ○ | Enable evasion of diagnostic/detection modalities |
| ○ | ○ | Enable the weaponization of a biological agent or toxin |
| ○ | ○ | Any other potentially harmful combination of experiments and agents |

## ChIP-seq

### Data deposition

☐ Confirm that both raw and final processed data have been deposited in a public database such as GEO.

☐ Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.

Data access links

*May remain private before publication.*

Files in database submission

Genome browser session

(e.g. UCSC )

### Methodology

Replicates

Sequencing depth

Antibodies

Peak calling parameters

Data quality

Software

## Flow Cytometry

### Plots

Confirm that:

☐ The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).

☐ The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).

☐ All plots are contour plots with outliers or pseudocolor plots.

☐ A numerical value for number of cells or percentage (with statistics) is provided.

### Methodology

Sample preparation

Instrument

Software

Cell population abundance

Gating strategy

☐ Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.

## Magnetic resonance imaging

### Experimental design

Design type

Design specifications

Behavioral performance measures

### Acquisition

Imaging type(s)

Field strength

Sequence & imaging parameters

Area of acquisition

Diffusion MRI ○ Used ○ Not used

### Preprocessing

Preprocessing software

Normalization

Normalization template

Noise and artifact removal

Volume censoring

### Statistical modeling & inference

Model type and settings

Effect(s) tested

Specify type of analysis: ○ Whole brain ○ ROI-based ○ Both

Statistic type for inference (See Eklund et al. 2016 )

Correction

## Models & analysis

n/a | Involved in the study

- Functional and/or effective connectivity
- Graph analysis
- Multivariate modeling or predictive analysis

Functional and/or effective connectivity

Graph analysis

Multivariate modeling and predictive analysis